by lorenzgerber | Mar 26, 2024 | Events
SAN DIEGO & SINGAPORE–(BUSINESS WIRE)–ImmunoScape, a biotechnology company focused on next-generation T Cell receptor (TCR)-based immunotherapies, today announced that three abstracts have been accepted for poster presentations at the 2024 American...
by lorenzgerber | Mar 1, 2024 | Events
ImmunoScape Leadership to Present at Upcoming Industry Conferences CEO Choon-Peng Ng and Vice President of Innovation, Michael Fehlings, Ph.D., will discuss Asia’s role in the “golden age” of biotech and AI in therapeutics SAN DIEGO, Calif., and Singapore – March 1,...
by lorenzgerber | Jan 5, 2024 | News
2023 was an exciting year at ImmunoScape, featuring transformative technical progress, new partnerships, expert additions to our leadership team and more. Read our latest newsletter for a look back at the highlights as well as a look ahead at what’s on the way for...
by lorenzgerber | Dec 21, 2023 | News
The collaboration seeks to produce novel off-the-shelf TCR-based bispecific molecules designed to overcome current limitations in cell therapy approaches against solid tumors SAN DIEGO, Calif., and Singapore – December 21, 2023 – ImmunoScape, a biotechnology...
by lorenzgerber | Dec 20, 2023 | News
MiNK Therapeutics combines its unique, proprietary library of T-cell antigens with ImmunoScape’s cutting-edge platform for rapid discovery of novel T-cell receptors Therapeutic development to focus on novel cell therapies as well as bispecific immune cell...
by lorenzgerber | Dec 19, 2023 | News
Therapeutics for solid tumors remain in a nascent corner of cancer research despite representing 90% of all cancers in adults. Thirty years after the first Chimeric Antigen Receptor was reported, CAR-T cell therapies have seen significant breakthroughs managing liquid...
by lorenzgerber | Dec 19, 2023 | Events
The ImmunoScape team is heading to the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco in a few weeks. Our CEO Choon-Peng (Choon) Ng, our Vice President, Discovery Dan MacLeod, and our Senior Director, Business Development Christopher Alfonso will be in...
by lorenzgerber | Dec 12, 2023 | News
ImmunoScape Appoints Systems Immunology and Computational Biology Expert Dr. John Tsang to its Scientific Advisory Board Expertise from award-winning computational biologist, human immunologist and engineer with experience from Yale, NIH, and NIAID will help advance...
by lorenzgerber | Nov 4, 2023 | News
ImmunoScape’s Andreas Wilm offers a behind the scenes look at the machine learning models we trained for research published in Cell Press’ Cell Reports – which validated ImmunoScape’s platform by accurately predicting T-cell antigen specificity through...
by lorenzgerber | Oct 19, 2023 | News
ImmunoScape Uses Machine Learning to Accurately Predict Antigen Specificity Based on T-Cell Phenotypes in New Peer-Reviewed Research ImmunoScape’s platform accelerates the discovery of efficacious TCR-based therapeutics for solid tumors SAN DIEGO, Calif., and...
